Radionuclide evaluation of relationship between the left ventricle pefusion and function and the serum level of brain natriuretic peptide in cases of coronary artery disease
Keywords:
BNP, coronary artery disease, perfusion scyntygraphy, radionuclide ventryculography, left ventricle perfusion and functionAbstract
The impairment of myocardial contractility is the consequence of the coronary artery disease (CAD). It is connected with the increase of serum natriuretic peptides of which the most important is brain natri-uretic peptide (BNP). The question if the impairment of left ventricle perfusion without coexisting func-tional disorder influences the rise of the BNP serum level is still not explained. Material and methods: The study was carried out in 133 patients with diagnosed CAD and in 18 healthy volunteers. Conducted research included radionuclide ventriculography, perfusion scyntigraphy of the heart muscle and the measurement of plasma BNP level. Results: BNP concentration was significantly higher in patients with CAD than in controls. In patients with CAD and the left ventricle ejection fraction (LVEF) lower than 50% BNP concentration was significantly higher than in patients with LVEF .2 50%. In groups with im-paired systolic/diastolic dynamics the BNP level was distinctly higher comparing to the group with nor-mal myocardial contractility, but these differences were not statistically significant. There was no sub-stantial dependence found between the extent of the ischaemia. Results: The impairment of left ventricle function caused by CAD induced plasma BNP level elevation proportional to the degree of the disorder whereas the myocardial perfusion disturbances without the functional consequences did not influence the BNP plasma concentration.
Downloads
References
Ganz P., Ganz W., Coronary blood flow and myocardial ischemia, z Braunwald E., Zipes D.P., Libby P., Heart disease. A textbook of cardiovascular medicine, W.B. Saunders Company, Philadelphia, London, New York, St. Louis, Toronto, 2001.
Libby P. The vascular biology of atherosclerosis, z Braunwald E., Zipes D.P., Libby P., Heart disease. A textbook of cardiovascular medicine, W.B. Saunders Company, Philadelphia, London, New York, St. Louis, Toronto, 2001.
Opie L.H., Mechanisms of cardiac contraction and relaxation, z Braunwald E., Zipes D.P., Libby P., Heart disease. A textbook of cardiovascular medicine, W.B. Saunders Company, Philadelphia, London, New York, St. Louis, Toronto, 2001.
Witkowska M., Co dziś trzeba wiedzieć o rozkurczowej niewydolności serca, Kardiol Pol 2001, 55, 603–606.
Chrzanowski Ł., Peptydy natriuretyczne – nowe możliwości zastosowania w diagnostyce i leczeniu chorób układu krążenia, Pol Przeg Kardiol 2002, 4, 2, 171–173.
Gackowski A., Isnard R., Piwowarska W., Komajda M., Peptyd natriuretyczny typu B., Kardiol Pol. 2002, 56, 644.
Tylicki L., Manitius J., Rutkowski B., Zastoinowa niewydolność krążenia. Nerkowa regulacja wydalania sodu i wody, Kardiol Pol 1997, 47, 47.
Yoshimura M., Mizuno Y., Harada E., Nakayama M., Shimasaki Y., Ito T., Interaction on Metabolic Clearance Between A-Type and B-Type Natriuretic Peptides in Patients With Heart Failure, Metabolism 2000, 49, 9, 1228–1233.
Kyriakides Z.S., Markianos M., Michalis L., Antoniadis A., Nikolaou N.I., Kremastinos D.T., Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty, Clin Cardiol. 2000 Apr; 23(4): 285–8.
Sudoh T., Minamino N., Kangawa K., Matsuo H., A new natriuretic peptide in human brain, Nature 1988; 332: 78–81.
Cowie M.R., BNP: soon to become a routine measure in the care of patients with heart failure? Heart 2000, 83, 617018.
Cheung BMY., Kumana CR., Natriuretic peptides- revelance in cardiac disease, JAMA 1998, 280, 1983–4.
Cowie M.R., Mendez G.F., BNP and congestive heart failure, Prog Cardiovasc Dis, 2002 Jan-Feb; 44(4): 293–321.
Maeda K., Takayoshi T., Wada A., Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction, Am HeartJ 1998, 135, 825–32.
McDonagh T.A., Robb S.D., Murdoch D.R., Biochemical detection of left-ventricular systolic dysfunction, Lancet 1998, Jan 3, 351 (9095), 9–13.
Arad M., Elazar E., Shotan A., Klein R., Rabinowitz B., Brain and atrial natriuretic peptides in patients with ischemic heart disease with and without heart failure, Cardiology. 1996 Jan-Feb; 87(1):12–7.
Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., Whooley M.A., Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study, Am J Med. 2004 Apr 15; 116(8):509–16.
Deo R., de Lemos J.A., B-type natriuretic peptide In ischemic heart disease, Curr Cardiol Rep, 2003 Jul; 5(4): 271–7.
McCullough P.A., Omland T., Maisel A.S., B-type natriuretic peptides: a diagnostic breakthrough for clinicians, Rev Cardiovasc Med, 2003 Spring; 4(2): 72–80.
Richards M., Nicholls M.G., Espiner E.A., Lainchbury J.G., Troughton R.W., Comparison of B-Type Natriuretic Peptides for Assessment of Cardiac Function and Prognosis In Stable Ischemic Hart Disease, J Am Coll Kardiol 2006; 47; 52–60.
Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., Whooley M.A., B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul Study, Circulation, 2003 Dec 16; 108(24): 2987–92.
Casco V.H., Veinot J.P., Kuroski de Bold M.L, Masters RG., Stevenson MM., de Bold AJ., Natriuretic Peptide System Gene Expression in Human Coronary Arteries, Journal of Histochemistry&Cytochemistry, vol 50(6): 799–809, 2002.
Goetze J.P., Christoffersen C., Perko M., Arendrup H., Rehfeld JF., Kastrup J., Increased cardiac BNP expression associated with myocardial ischemia, The FASEB Journal, 2003, vol 17, 1105–1107.
Nakamura T., Sakamoto K., Yamano T., Kikkawa M., Zen K., Hikosaka T., Increased Plasma Brain Natriuretic Peptide Level as a Guide for Silent Myocardial Ischemia in Patients With Non-Obstructive Hypertrophic Cardiomyopathy, J Am Coll of Cardiol, 39, 10, 2002.
Sabatine M.S., Morrow D.A., de Lemos J.A., Omland T., Desai M.Y., Tanasijevic M., Acute Changes in circulating Natriuretic Peptide Levels in Relation to Myocardial Ischemia, Journal of the American College of Cardiology, Vol 44, No.10, 2004.
Pasierbski T., Miśko J., Badania radioizotopowe w diagnostyce choroby wieńcowej w Polsce (AD 2004), Kardiol Pol. 2004, 60, 626.
Poprawski K., Wierzchowiecki M., Choroba niedokrwienna serca. Diagnostyka nieinwazyjna. Nowe możliwości i perspektywy, Kariol Pol 1996, 45, 341.
Tarkowska A., Adam WE, Bitter F., Ocena regionalnej czynności lewej komory serca za pomocą metody parametrycznych scyntygrafów, Pol Przegl Rad Med Nukl, 1982, XLVI, 1–3, 83–88.
Adam W.E., Tarkowska A., Evaluation of myocardial function using gated blood pool procedures, z Pobst H.W., Adam W.E., Ell P., Hör F., Kriegel H., Handbook of Nuclear Medicine, Vol. 2: Heart, G. Fisher Verlag, Stuttgard, Yena, Nem York, 1992.
Faber T.L., Akers M.S., Peshock R.M., Corbett J.R., Three-Dimensional Motion and Perfusion Quantification in Gated Single-Photon Emission Computed Tomograms, J Nucl Med 1991; 32: 2311–2317.
Gremillet E., Champailler A., Soler C., Fourier Temporal Interpolation Improves Electrocardiograph-Gated Myocardial Perfusion SPECT, J Nucl Med 2005, 46; 1769–1774.
Tarkowska A., Cholewiński W., Stefaniak B., Evolution of 99mTc tetrofosmin myocardial uptake defects during 3 hrs after physicial stress in pts with CAD, Eur J Nucl Med, 2002, 29, Sup. 1. S97.
Davidson N.C., Naas A.A., Hanson J.K., Kennedy N.S., Coutie W.J., Struthers A.D., Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction, Am J Cardiol, 1996 Apr 15; 77(10):828–31.
Valli N., Georges A., Corcuff J.B., Barat J.L., Bordenave L., Assessment of brain natriuretic peptide in patients with suspected heart failure: comparison with radionuclide ventriculography data, Clin Chim Acta, 2001 Apr; 306(1–2): 19–26.
Kouris K., Abel-Dayem HM, Taha B., Ballani N., Hassan I.M., Constantinides C., Left ventricular ejection fraction and volumes calculated from dual gated SPECT myocardial imaging with 99Tcm-MIBI, Nucl Med Commun 1992; 13(9): 648–55.
Wright G.A., McDade M., Kneble W., Martin W., Hutton I., Are ejection fractions from gated SPECT perfusion studies clinically useful? A comparison with radionuclide ventriculography, Physiol Meas 2001; 22(2): 413–22.
Bettencourt P., Ferreira A., Pardal-Oliveira N., Pereira M, Queiros C., Araujo V., Clinical significance of brain natriuetic peptide in patients with postmyocardial infarction, Clin Cardiol 20000, 23 (12): 921–7.
Darbar D., Davidson N.C., Gillespie N., Choy A.M., Lang C.C., Shyr Y., Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction, Am J Cardiol, 1996 Aug 1; 78(3): 284–7.
Futterman L.G, Lemberg L., Novel markers in the acute coronary syndrome: BNP, IL-6, PAPP-A, Am J Crit Care, 2002 Mar; 11(2): 168–72.
Jernberg T., James S., Lindahl B., Johnston N., Strisberg M., Venge P., Wallentin L., Natriuretic peptides in unstable coronary artery disease, European Heart Journal 2004, 25, 1486–1493.
Palazzuoli A., Calabria P., Vcchiato L., Quatrini I., Carrera A., Bruni F., Plasma brain natriuretic peptide levels in coronary heart disease with preserved systolic function, Clin Exp Mad 2004, 3: 44–49.
Weber M., Dill T., Arnold R., Rau M., Ekinci O., Muller K., N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris, American Heart Journal, 2004, Vol 148, 4.
Celiński R., Cholewiński W., Stefaniak B., Tarkowska A., Relationship between plasma BNP levels and left ventricular diastolic function as measured by radionuclide ventriculography in patients with coronary artery disease, Nucl Med Rev 2004, 2, 123–128.
Celiński R., Grzywa-Celińska A., Cholewiński W., Stefaniak B., Tarkowska A., Ocena zależności między stężeniem mózgowego peptydu natriuretycznego we krwi a funkcją skurczową komory lewej w chorobie niedokrwiennej serca, Pol Merk Lek 2005, XVIII, 105, 291.
Celiński R., Grzywa-Celińska A., Cholewiński W., Stefaniak B., Tarkowska A., Poziom BNP we krwi a perfuzja i funkcja komory lewej w przypadkach choroby niedokrwiennej serca, Problemy Medycyny Nuklearnej 2004; 18(36): 143–152.
Dahlstrom U., Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail, Mar 15; 6(3): 281–7.
Lukowicz T.V., Fischer M., Hense H.W., Doring A., Stritzke J., Riegger G., BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy, Eur J Heart Fail, 2005 Jun; 7(4): 525–31.
Nakae I., Matsuo S., Koh T., Mitsunami K., Horie M., Left ventricular systoli/diastoli function evaluated by quantitive ECG-gated SPECT: comparison with echocardiography and plasma BNP analysis, Ann Nucl Med, 2005, 19, 6, 447–454.
Yamaguchi H., Yoshida J., Yamamoto K., Sakata Y., Mano T., Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy, J Am Coll Cardiol, 2004 Jan 7; 43(1): 55–60.
Arques S., Roux E., Sbragia P., Ambrosi P., Taieb L., Pieri B., Accuracy of Tissue Doppler Echocardiography in the Emergency Diagnosis of Decompensated Heart Failure with Preserved Left Ventricular Systolic Function: Comparison with B-Type Natriuretic Peptide Measurement, Echocardiography, Vol 22, No. 8, 2005.
Clarkson P.B.M., Wheeldon N.M., MacFadyen R.J., Pringle S.D., MacDonald T.M., Effects of Brain Natriuretic Peptide on Exercise Hemodynamics and Neurohormones in Isolated Diastolic Heart Failure, Circulation, 93, 11, 1996.
Takase H., Toriyama T., Sugiura T., Ueda R., Dohi Y., Brain natriuretic peptide In the prediction of recurrence of angina pectoris, Eur J Clin Incest 2004, 34, 79–84.
Nishikimi T., Mori Y., Ishimura K., Tadokoro K., Yagi H., Yale A., Association of Plasma Atrial Natriurteic Peptide, N-Terminal Proatrial Natriuretic Peptide, and Brain Natriuretic Peptide Levels with Coronary Artery Stenosis In Patients with Normal Left Ventricular Systolic Function, Am J Med 2004; 116: 517–523.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2007 Medical Journal of the Rzeszow University
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
